title: Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder.
abstract: OBJECTIVE
  To investigate the expression of ezrin, HGF and c-met in the benign and malignant lesions of the gallbladder.
  
  
  METHODS
  Ezrin, HGF and c-met expression was detected by immunohistochemistry.
  
  
  RESULTS
  The positive ezrin, HGF and c-met expression was significantly higher in gallbladder adenocarcinoma than in benign lesions. The benign lesions with positive ezrin, HGF and/or c-met expression showed moderately- or severely-atypical hyperplastic epithelium. The positive expression of ezrin, HGF and c-met was significantly associated with differentiation, tumor mass, lymph node metastasis and invasion of adenocarcinoma. Univariate Kaplan-Meier analysis showed that increased expression of ezrin, HGF and c-met was associated with decreased overall survival. Multivariate Cox regression analysis showed that increased expression of ezrin, HGF or c-met was an independent bad-prognostic predictor in gallbladder adenocarcinoma.
  
  
  CONCLUSIONS
  The expression of ezrin, HGF and/or c-met might be closely related to the carcinogenesis, progression, clinical biological behaviors and prognosis of gallbladder adenocarcinoma.
authors.affiliation: Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Hunan, China.
authors.forename: Leping
authors.initials: L
authors.lastname: Yang
authors.forename: Tanxing
authors.initials: T
authors.lastname: Guo
authors.forename: Song
authors.initials: S
authors.lastname: Jiang
authors.forename: Zhulin
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality / Q000556:secondary; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D016009:Chi-Square Distribution; D002681:China; D003598:Cytoskeletal Proteins / Q000032:analysis*; D005260:Female; D005704:Gallbladder / Q000737:chemistry* / Q000473:pathology; D005705:Gallbladder Diseases / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005706:Gallbladder Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D017228:Hepatocyte Growth Factor / Q000032:analysis*; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016016:Proportional Hazards Models; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D047368:Tumor Burden; D015854:Up-Regulation; D000099149:Ezrin
chemical_list: D014408:Biomarkers, Tumor; D003598:Cytoskeletal Proteins; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met; D000099149:Ezrin; C066855:HGF protein, human